UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach. They developed nanoparticle carriers to successfully deliver therapeutic doses of a cancer drug that had previously failed clinical development due to pharmacologic challenges. They report their proof of principle findings in the April 30, 2012 early online edition of Proceedings of the National Academy of Sciences.
UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
Thu 3 May 12 from Nanotechweb
UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery, Wed 2 May 12 from HealthCanal
UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery, Wed 2 May 12 from e! Science News
UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery, Wed 2 May 12 from Eurekalert
Study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach. They developed nanoparticle carriers to successfully ...
Wed 2 May 12 from Phys.org
Study shows potential to revive abandoned cancer drug by nanoparticle drug delivery, Thu 3 May 12 from Labspaces.net
Nanoparticle Formulation Revives Abandoned Cancer Drug, Thu 3 May 12 from AZoNano
Nanoparticle Drug Delivery Can Restore Clinical Potential of Abandoned Cancer Drugs
By Cameron Chai A UNC research team has demonstrated that nanoparticles can revive the clinical potential of several cancer drugs that had unsuccessful clinical development because of pharmacologic...
Fri 4 May 12 from AZoNano
Potential to revive abandoned cancer drug by nanoparticle drug delivery
Researchers have developed nanoparticle carriers to successfully deliver therapeutic doses of a cancer drug that had previously failed clinical development due to pharmacologic challenges.
Wed 2 May 12 from ScienceDaily
- Pages: 1
Bookmark
